We are live on ! Find out more
ALGS icon

Aligos Therapeutics
ALGS

35 hedge funds and large institutions have $27.1M invested in Aligos Therapeutics in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

15.26% more ownership

Funds ownership: 46.8% → 62.06% (+15%)

3% more funds holding

Funds holding: 34 → 35 (+1)

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

58% less capital invested

Capital invested by funds: $64.5M → $27.1M (-$37.4M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $14K

Holders
35
Holders Change
+1
Holders Change %
+2.94%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
9
Reduced
9
Closed
9
Calls
–
Puts
$14K
Net Calls
-$14K
Net Calls Change
-$14K

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$9.03M
2
WP
Woodline Partners
California
+$6.91M
3
HCM
Heights Capital Management
California
+$5.29M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$5.29M
5
DTC
Deep Track Capital
Connecticut
+$4.38M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$3.66M
2
VC
Vivo Capital
California
-$2.89M
3
IC
Ikarian Capital
Texas
-$2.56M
4
UOC
UBS O'Connor
Illinois
-$1.6M
5
AAS
Avantax Advisory Services
Texas
-$1.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$69.8K -$155K -7,060 -45%
Morgan Stanley
27
Morgan Stanley
New York
$61.9K +$93.5K +4,265 +132%
GSWM
28
Golden State Wealth Management
California
$22.1K – – –
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$18K -$458K -20,883 -91%
TRCT
30
Tower Research Capital (TRC)
New York
$10.1K +$12.5K +569 +87%
Osaic Holdings
31
Osaic Holdings
Arizona
$1.81K -$14.8K -675 -75%
JP Morgan Chase
32
JP Morgan Chase
New York
$215 – – –
SS
33
SBI Securities
Japan
$132 -$3.4K -155 -91%
EWP
34
Elevation Wealth Partners
California
$33 – – –
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$25 – – –
IC
36
Ikarian Capital
Texas
– -$2.56M -64,300 Closed
UOC
37
UBS O'Connor
Illinois
– -$1.6M -40,096 Closed
AAS
38
Avantax Advisory Services
Texas
– -$1.22M -30,570 Closed
DWM
39
Drive Wealth Management
Utah
– -$916K -23,000 Closed
BFM
40
Boothbay Fund Management
New York
– -$739K -18,543 Closed
State Street
41
State Street
Massachusetts
– -$382K -9,582 Closed
Northern Trust
42
Northern Trust
Illinois
– -$205K -5,157 Closed
SWM
43
Spire Wealth Management
Virginia
– -$7.97K -200 Closed
AWM
44
Avior Wealth Management
Nebraska
– -$3.19K -80 Closed
1
2

ALGS Hedge Fund Activity: Q1 2025 in Review

35 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2025, worth a combined $27.1M — down 58% from $64.5M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ALGS positions and 9 closed out — a net gain of 2 holders — while 9 added to existing stakes and 9 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $9.03M. The largest seller was EcoR1 Capital, cutting an estimated $3.66M.

  • 35 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2025, up from 34 in Q4 2024.
  • Funds reported $27.1M of Aligos Therapeutics stock for Q1 2025, down 58% quarter-over-quarter.
  • 11 funds opened new Aligos Therapeutics positions in Q1 2025 and 9 closed out, a net change of +2 holders.
  • The largest Aligos Therapeutics buyer in Q1 2025 was Alyeska Investment Group, an estimated $9.03M added.
  • The largest Aligos Therapeutics seller in Q1 2025 was EcoR1 Capital, an estimated $3.66M sold.

Based on aggregated 13F filings for Q1 2025.